Prof. Dr. Meral Beksaç

Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic

Bone Marrow Transplantation, 2012

DOI 10.1038/bmt.2011.240 PMID 22139068 12 atıf (Europe PMC) Kaynak: ORCID

Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

Blood, 2012

DOI 10.1182/blood.v120.21.4904.4904 Kaynak: ORCID

Management of treatment-emergent peripheral neuropathy in multiple myeloma

Leukemia, 2012

DOI 10.1038/leu.2011.346 PMID 22193964 193 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma

Blood, 2012

DOI 10.1182/blood.v120.21.3024.3024 Kaynak: ORCID

Myeloma as a second malignancy following AML: Is a second allo equivalent to auto?

Case Reports in Medicine, 2012

DOI 10.1155/2012/319530 PMID 22811719 Açık erişimli tam metinKaynak: ORCID

PANORAMA 1: A PHASE III STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA

Haematologica, 2012

Kaynak: ORCID

Predictive value of pre-transplant FDG-PET/CT in newly diagnosed multiple myeloma (MM) patients

European Journal of Nuclear Medicine and Molecular Imaging, 2012

Kaynak: ORCID

Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.

Journal of Clinical Oncology, 2012

DOI 10.1200/jco.2012.30.15_suppl.8095 14 atıf (OpenAlex) Kaynak: OpenAlex

Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).

Journal of Clinical Oncology, 2012

DOI 10.1200/jco.2012.30.15_suppl.e21006 Kaynak: OpenAlex

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015

Blood, 2011

DOI 10.1182/blood.v118.21.475.475 20 atıf (OpenAlex) Kaynak: ORCID

Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

Blood, 2011

DOI 10.1182/blood-2010-10-299529 PMID 21292778 290 atıf (Europe PMC) Kaynak: ORCID

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups

Blood, 2011

Kaynak: ORCID

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC

Blood, 2011

DOI 10.1182/blood.v118.21.257.257 4 atıf (OpenAlex) Kaynak: ORCID

LONG-TERM SURVIVORSHIP AFTER ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION: STILL ONGOING NON RELAPSE RELATED MORTALITY & MORBIDITY

Biology of Blood and Marrow Transplantation, 2011

DOI 10.1016/j.bbmt.2010.12.265 Açık erişimli tam metinKaynak: ORCID

Long-term outcome in patients surviving 5 or more years after allogeneic haematopoetic cell transplantation

Bone Marrow Transplantation, 2011

Kaynak: ORCID

Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

Oncologist, 2011

DOI 10.1634/theoncologist.2010-0386 PMID 21441574 21 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement

Leukemia, 2011

DOI 10.1038/leu.2011.3 PMID 21293488 89 atıf (Europe PMC) Kaynak: ORCID

Peripheral stem cell apheresis in multiple myeloma in the era of new agents

Bone Marrow Transplantation, 2011

Kaynak: ORCID

Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

Blood, 2011

DOI 10.1182/blood-2011-06-358812 PMID 21841166 254 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial

Leukemia Research, 2011

DOI 10.1016/j.leukres.2010.07.005 PMID 20673585 12 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up

Journal of Clinical Oncology, 2011

DOI 10.1200/jco.2010.32.7312 PMID 21730266 136 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Blood, 2011

DOI 10.1182/blood-2011-03-341669 PMID 21670471 188 atıf (Europe PMC) Kaynak: ORCID

The role of second allogeneic haematopoietic cell transplantation on relapse of haematological diseases

Bone Marrow Transplantation, 2011

Kaynak: ORCID

The shaping of modern human immune systems by multiregional admixture with archaic humans

Science, 2011

DOI 10.1126/science.1209202 PMID 21868630 333 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

First and Second High Dose Treatment Supported by Autologous Hematopoetic Cell Transplantation Rescue in Multiple Myeloma

Blood, 2011

DOI 10.1182/blood.v118.21.4528.4528 Kaynak: OpenAlex

Immunophenotyping Features in Acute Myeloid Leukemia (AML) with NPM1+ and/or FLT3+

Blood, 2011

DOI 10.1182/blood.v118.21.4908.4908 Kaynak: OpenAlex

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

European Journal Of Haematology, 2010

DOI 10.1111/j.1600-0609.2010.01524.x PMID 20942865 110 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells

Cytotherapy, 2010

DOI 10.3109/14653249.2010.510506 PMID 20735163 26 atıf (Europe PMC) Kaynak: OpenAlex

A case of langerhans cell histiocytosis with central diabetes insipidus, hypopituitarism and pulmonary involvement,Santral diabetes i̇nsipidus, hipopituitarizm ve pulmoner tutulum ile giden langerhans hücreli histiyositoz olgusu

Turkiye Klinikleri Journal of Medical Sciences, 2010

DOI 10.5336/medsci.2008-8695 Açık erişimli tam metinKaynak: ORCID

ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION IN PATIENTS POSITIVE FOR HEPATITIS B SURFACE ANTIGEN

Biology of Blood and Marrow Transplantation, 2010

DOI 10.1016/j.bbmt.2009.12.395 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

Allogeneic haematopoetic cell transplantation in hepatitis B surface antigen positive recipients

Bone Marrow Transplantation, 2010

Kaynak: ORCID

Allogeneic haematopoietic cell transplantation in paroxysmal nocturnal haemoglobinuria: a therapeutic dilemma from start to discharge

Bone Marrow Transplantation, 2010

DOI 10.1038/bmt.2010.45 Açık erişimli tam metinKaynak: ORCID

Bronchiolitis obliterans after allogeneic haematopoietic cell transplantation: inpredictable and fatal

Bone Marrow Transplantation, 2010

Kaynak: ORCID

Comparison of the most frequent haplotypes of Turkish subjects in two registries: TRAN and DKMS

Tissue Antigens, 2010

Kaynak: ORCID

Comparison of two different chemotherapy regimens for peripheral blood stem cell mobilization in lymphoma

Bone Marrow Transplantation, 2010

Kaynak: ORCID

Current multiple myeloma treatment strategies with novel agents: A European perspective

Oncologist, 2010

DOI 10.1634/theoncologist.2009-0203 PMID 20086168 69 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Donor safety: The role of the WMDA in ensuring the safety of volunteer unrelated donors: Clinical and ethical considerations

Bone Marrow Transplantation, 2010

DOI 10.1038/bmt.2010.2 PMID 20173787 39 atıf (Europe PMC) Kaynak: ORCID

Long-term follow-up of upfront tandem autologous - RIC (reduced intensity conditioning) allogeneic transplantation versus autologous transplantation (NMAM2000) in multiple myeloma

Bone Marrow Transplantation, 2010

Kaynak: ORCID

Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: A randomised trial

The Lancet Oncology, 2010

DOI 10.1016/s1470-2045(09)70352-3 PMID 20117965 103 atıf (Europe PMC) Kaynak: ORCID

MP VERSUS MPT FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A META ANALYSIS OF SURVIVAL OF 1682 INDIVIDUAL PATIENT DATA FROM 6 RANDOMIZED CLINICAL TRIALS

Haematologica, 2010

Kaynak: ORCID

Multiple Myeloma Patients Who Are Chemosensitive and Present with Plasma Cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose Therapy and Autologous Stem Cell Transplantation More

Blood, 2010

DOI 10.1182/blood.v116.21.1345.1345 Kaynak: ORCID

PRESENCE OF ABNORMAL PLASMA CELLS IN PERIPHERAL STEM CELL HARVEST PRODUCTS PREDICT EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

Biology of Blood and Marrow Transplantation, 2010

DOI 10.1016/j.bbmt.2009.12.257 Açık erişimli tam metinKaynak: ORCID

RANDOMIZED PHASE 2 TRIAL OF BORTEZOMIB-DEXAMETHASONE (VD) VERSUS VD PLUS CYCLOPHOSPHAMIDE OR LENALIDOMIDE IN MYELOMA PATIENTS ACHIEVING STABLE DISEASE AFTER 4 CYCLES OF VD AS SECOND-LINE TREATMENT

Haematologica, 2010

Kaynak: ORCID

Use of High-Dose Chemotherapy plus Granulocyte Colony-Stimulating Factor for the Salvage of Refractory or Resistant-Relapse Lymphoma Patients without Stem Cell Support

Acta Haematologica, 2009

DOI 10.1159/000203607 PMID 9352743 Kaynak: OpenAlex

5-azacytidine treatment results in myelodysplastic syndrome

Journal of Clinical Oncology, 2009

DOI 10.1200/jco.2009.27.15_suppl.e18003 Kaynak: ORCID

Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group

Blood, 2009

Kaynak: ORCID

Autologous stem cell transplantation (ASCT) versus ASCT followed by reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling donor in previously untreated multiple myeloma (MM): a prospective controlled trial by the EBMT

Bone Marrow Transplantation, 2009

Kaynak: ORCID

HLA specificities/haplotypes of patients who have no matched donors available worldwide: a report from TRAN-Turkey

Tissue Antigens, 2009

Kaynak: ORCID

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Leukemia, 2009

DOI 10.1038/leu.2009.89 PMID 19421229 299 atıf (Europe PMC) Kaynak: ORCID

Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF

Bone Marrow Transplantation, 2009

DOI 10.1038/bmt.2009.161 PMID 19597420 12 atıf (Europe PMC) Kaynak: ORCID